Opinion

Video

Patient Burden Associated with Pneumococcal Disease

Author(s):

Christina M. Madison, PharmD, FCCP, AAHIVP,Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP

A medical professional examines the significant patient burden imposed by pneumococcal infections, highlighting how this burden drove the development of innovative vaccine technologies.

  1. Discuss the patient burden of pneumococcal infections that led to the development of novel vaccines.
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
When to Call, When to Counsel: Fluoroquinolone Tendinopathy
December 17th 2024

When to Call, When to Counsel: Fluoroquinolone Tendinopathy

K. Ashley Garling, PharmD RahJewel Barnhill, PharmD Candidate
Site Logo
December 20th 2024

Examining the 505(b)(2) Pathway and Implementation into EHR

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Research Reveals Opportunities for Antimicrobial Stewardship When Treating Community-Acquired Pneumonia
December 10th 2024

Research Reveals Opportunities for Antimicrobial Stewardship When Treating Community-Acquired Pneumonia

Aislinn Antrim, Assistant Managing Editor
PPSV23, hospitalization, pneumonia, pneumococcal, CAP | Image Credit: © Bernard Chantal | stock.adobe.com
December 10th 2024

PPSV23 Prevents Hospitalization Risk Due to Community-Acquired Pneumonia

Ashley Gallagher, Associate Editor
Pneumococcal, Low-Risk, Multiple Myeloma | Image Credit: © Minerva Studio | stock.adobe.com
December 3rd 2024

Pneumococcal Infection Reveals Underlying Immunosuppressive Conditions for Low-Risk Adults

Ashley Gallagher, Associate Editor
Pneumococcal vaccine bottles and syringes for preventing pneumonia.
November 29th 2024

Childhood Pneumococcal Vaccination Programs Indirectly Protect Adults From Pneumococcal Disease

Luke Halpern, Assistant Editor